Open access
Sep 2026
Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.
Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.
M. Szarek, Deepak L. Bhatt, Michael Miller et al.
· Journal of Clinical Lipidolo... · 0 citations